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Objective.
 
 To assess prescription renewal and switch
rates in an elderly population receiving oxybutynin or fla-
voxate for treatment of urinary incontinence in Quebec.
 
Methods.
 
 Sociodemographic, clinical, and drug claim
data for patients 
 

 
65 years of age, with at least one
claim for oxybutynin or flavoxate between January 1,
1994 and December 31, 1997, were randomly ex-
tracted from a database maintained by the Régie de
l’assurance maladie du Québec (RAMQ). Rates of re-
newal of the first drug claim and the number of patients
switching from one incontinence drug to the other were
determined. In addition, survival curves defining the time
until cessation of initial treatment were constructed.
 
Results.
 
 The oxybutynin (
 
n
 
 
 

 
 5718) and flavoxate (
 
n
 
 
 

 
972) treatment groups were similar in terms of gender
(62.1% female) and age (mean age 77). For oxybuty-
nin, 56.8% of the claims were written by general practi-
tioners and 36.6% by urologists compared to 40.5% by
general practitioners and 51.4% by urologists for fla-
voxate. Only 39.3% of the oxybutynin patients re-
newed their first claims, compared to 36.6% of the fla-
voxate group. Switch rates were higher for flavoxate
patients with more than twice as many patients switch-
ing from this drug to oxybutynin than vice versa. Sur-
vival curves indicated that there was only an 11.4%
probability of a patient taking oxybutynin for 6 months
compared to 5.7% for flavoxate patients.
 
Conclusions.
 
 Drug claim renewal rates were low for
both oxybutynin and flavoxate, suggesting that money
spent on these therapies provides an inadequate clinical
return on investment since the majority of patients dis-
continue treatment prematurely.
 
Introduction
 
Urinary incontinence (UI), a general term referring
to any disturbance of the normal storage and
voiding of urine, is a relatively common problem
in elderly individuals and can have a profound ef-
fect on the quality of life and activities of daily liv-
ing in this population [1,2]. Because of differences
in the frequency of incontinence and the gender
and age of study subjects, prevalence estimates of
the condition vary widely with values ranging from
17% to 55% for older women and 11% to 34%
in men of the same age group [3]. Episodes of
daily incontinence are estimated to occur in 3% to
17% of elderly women and 2% to 11% of elderly
men [3]. In addition, up to 50% of nursing home
residents may experience UI [1,4].
This level of disease prevalence has consider-
able clinical and economic consequences [5–7].
While no figures exist for Canada, the most recent
assessment of the direct medical cost of UI in the
United States (1995) [8] was $25.6 billion. Incon-
tinent patients have an increased incidence of uri-
nary tract infections and falls, a higher risk of hos-
pitalization, and are generally hospitalized for
longer periods than their continent counterparts
[5–8]. These adverse consequences of UI have
been estimated to contribute $13.1 billion to the
total economic burden of the disease (51% of the
total) [8], representing a cost that could be re-
duced significantly with successful control of UI
symptoms.
Successful treatment of UI is contingent on an
accurate diagnosis and can involve behavioral
therapy, bladder education programs, fluid intake
changes, pelvic muscle exercises, and pharmaco-
therapy [9–11]. Although the choice of specific
pharmacological intervention is governed by the
type of UI diagnosed, the tertiary amine oxybuty-
nin has been used to treat the urinary urgency, fre-
quency, and urge incontinence associated with
overactive bladder due to detrusor instability [12–
14]. In Canada, oxybutynin is the most commonly
used medication for this specific type of inconti-
nence. The primary action of the anticholinergic
drug is a direct antispasmotic effect on the smooth
muscle of the bladder in addition to a neu-
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rotrophic action on muscarinic receptors control-
ling bladder contraction [12,15]. A second drug
used in the treatment of detrusor instability is the
smooth muscle relaxant flavoxate, although there
is little solid clinical evidence to suggest that the
drug is effective [16], which has led to a recom-
mendation by the Agency for Health Care Policy
And Research (AHCPR) [17] that it not be used in
the treatment of UI. Nevertheless, in Québec fla-
voxate is indicated for the treatment of inconti-
nence and is listed in the same therapeutic class as
oxybutynin on the provincial formulary [18].
Hyoscyamine, another drug that has been used for
the treatment of detrusor instability [17] is not
listed on the formulary and is unavailable in Can-
ada in an oral formulation.
Clinical trials have shown that both oxybutynin
and flavoxate are associated with unpleasant side-
effects related to their anticholinergic activity pro-
file [10,12,16]. As a result, compliance in clinical
trials is poor, with many patients discontinuing
treatment [12,15], raising the issue of whether
current investments in UI pharmacotherapy pro-
vide adequate clinical returns. However, compli-
ance rates for incontinence medications have, for
the most part, been determined in the protocol-
driven environment of clinical trials, which may
not provide an accurate picture of drug use in ac-
tual clinical practice. Clinical experience suggests
that compliance is further decreased when UI
drugs are used in actual practice [19]. In the
present study, we have attempted to quantify com-
pliance by determining how oxybutynin and fla-
voxate are prescribed and used by patients in nor-
mal clinical practice by tracking prescription claims
in a large patient database maintained by health au-
thorities in Québec, Canada.
 
Methods
 
RAMQ Databases
 
Two databases maintained by the Régie de l’assur-
ance maladie du Québec (RAMQ) were utilized in
this study. In Québec it is through the RAMQ that
drug costs are reimbursed to pharmacists for indi-
viduals aged 65 years and older and for recipients
of social insurance. The two databases used were
a drug claim database and a medical services data-
base. The information recorded for each drug
claim includes patient and drug identifiers, drug
format (tablets, liquid, etc.), date the prescription
was filled, dosage, number of units dispensed, and
the duration of the prescription. The medical ser-
vices database records patient-physician visits and
contains information on patient identification, di-
agnosis (ICD9 code), and the date of each visit to
a specialist or general practitioner. Patient records
can be linked in both databases via the benefi-
ciary’s health insurance number, which is scram-
bled into a single patient identifier to ensure pa-
tient confidentiality.
 
Patient Selection
 
RAMQ was asked to provide records for patients,
65 years of age or older, who had at least one
claim for oxybutynin (Ditropan
 
®
 
) or flavoxate
(Urispas
 
®
 
) over a 4-year period (between January
1, 1994 and December 31, 1997). The appropri-
ate records were extracted randomly from the da-
tabase using a computerized selection system de-
veloped by RAMQ. Since it is normal policy for
RAMQ not to release all records for specific
drugs, the relevant information was provided for
33% of all patients who received oxybutynin and
50% of all patients who received flavoxate over
the designated period. For each patient we then
defined the date of the first claim within the 4-year
period as the index date. To ensure that there was
at least 6 months of follow-up information for
each patient, only patients whose first claim was
on or before July 1, 1997 were included in the
analysis. Patients with a claim for oxybutynin or
flavoxate during the year preceding the index date
or who died in the 6 months after the index date
were excluded. The relevant sociodemographic
and claims data were extracted for both the oxy-
butynin and flavoxate patients including the form
and quantity of the drug dispensed, the date and
duration of the claim, as well as the type of physi-
cian prescribing the drug. All patients prescribed
flavoxate received 200 mg tablets. For oxybuty-
nin, most patients received their medication as 5
mg tablets, except for some claims that were dis-
pensed as a syrup. To quantify daily intake in
these patients, the daily prescribed syrup was con-
verted to the number of units of 5 mg of oxybuty-
nin taken per day, based on a concentration of 1
mg/ml in the medication.
 
Assessment of Comorbidity of Selected Patients
 
Using the RAMQ records provided for each pa-
tient, an assessment of comorbidity was accom-
plished by measurement of chronic disease scores
(CDS). This technique, originally developed by
Von Korff et al. [20] uses patient prescription pat-
terns to provide a measure of an individual’s
chronic disease status. To quantify this parameter,
the medications used to treat specific diseases are
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assigned a weighting factor. Subsequently, a pa-
tient CDS is determined by adding up the appro-
priate weighting factors for each medication taken
for chronic conditions. Medications that are fre-
quently used only for symptom management (i.e.,
analgesics, anti-inflammatories, and antidepres-
sants) were not included in the analysis. The over-
all score ranges from zero to 14, zero being the
minimum score for comorbidity. For the present
study, CDS scores were based on an assessment of
the total patient prescription claim patterns at the
index date defining the first claim for either oxy-
butynin or flavoxate.
 
Data Analysis
 
Baseline sociodemographic and claim parameters
were analyzed for all the selected patients. To
quantify the length of time patients actually took
incontinence drugs, prescription renewal and switch
rates were determined for subjects initially dis-
pensed either oxybutynin or flavoxate. Drug claim
renewal rates were analyzed in two ways: rate of
renewal of the first claim over short and long
time-frames, and using survival curves to deter-
mine the probabilities of continuous prescription
renewal. For the former analysis, the rate of re-
newal of the first drug claim over a short time-
frame, which would suggest an initial desire by the
patient to stay on treatment, was defined as a re-
newal that took place within 1.5 times the dura-
tion of the previous claim from the index date
(date of the first claim). For example, a patient
with a first claim of a 30-day supply of medication
would have a total of 45 days (30-day drug supply
and a 15-day grace period) to renew the claim in
order to be considered still on treatment. When
the prescription was for less than 14 days, a pa-
tient was considered on continuous treatment if
the claim was renewed within a maximum period
of 7 days after completion of drug supply. Rates
of patient renewal of the first drug claim were also
assessed over longer time-frames, defined as a re-
newal that took place at any time during the 4-year
study period. This assessment was designed to
quantify the rate of sporadic renewal. Switch
rates, which assessed the rate of switching from
oxybutynin to flavoxate or flavoxate to oxybuty-
nin, were determined over short time-frames (1.5
times the duration of the previous drug claim).
Rates were determined either in patients with no
prescription renewals, or after any number of re-
newals, prior to the switch. Renewal and switch
rates were calculated as percentages, based on the to-
tal number of patients in each treatment group. A
chi-square test was performed to determine 
 
P
 
 values.
Survival curves were plotted for both the oxy-
butynin and flavoxate treatment groups. Survival
functions were based on the number of days from
the first claim to cessation of treatment. Cessation
was defined as a nonrenewal of the same drug, a
switch to the other drug, or censoring due to the
end of the data file or the death of the patient. A
patient was considered on treatment as long as the
drug claim was renewed within the short time-
frames defined above. Regression analysis of the
survival data was accomplished using a Cox’s
semiparametric model, adjusted for six patient
variables: daily drug quantity, type of prescribing
physician, patient age and sex, drug prescribed,
and CDS.
 
Results
 
From the drug claim data, 6690 patient records
(5718 for oxybutynin and 972 for flavoxate) met
the criteria defined for the study. The majority of
patients were female in both groups and the aver-
age age of the oxybutynin treatment group was
77.5 compared to 76.4 for flavoxate, a difference
(1.1 years) that was statistically significant (Table
1). The mean age of the overall RAMQ patient
population who were 65 years or older was 74.
Because patients of this age usually suffer from
more than one chronic condition, the CDS was
used to provide some measure of comorbidity in
both treatment groups. The CDS was identical for
both groups (Table 1) with a mean score of 2.6.
Patients with a CDS of zero numbered 32% while
approximately 24% had scores of five or higher.
There were statistically significant differences
(
 
P
 
 
 

 
 .001) in the treatment groups as to the type
of physician who initially prescribed the medica-
 
Table 1
 
Baseline sociodemographic and clinical 
characteristics of the patient populations
 
Variable
Oxybutynin 
(
 
n
 
 
 

 
 5718)
Flavoxate
(
 
n
 
 
 

 
 972)
Gender (%)
Male 2167 (37.9) 367 (37.8)
Female 3551 (62.1) 605 (62.2)
Mean age (years) 77.5 76.4
(95% CI)* (77.4, 77.6) (76.2, 76.6)
Chronic disease score
Mean* 2.6 2.6
(95% CI)* (2.6, 2.7) (2.4, 2.7)
 
P
 
 value for chronic disease scores for both groups was .85 (determined by a
T-test).
*Values in parentheses are the 95% confidence intervals.
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tion at the index date and the daily dispensed dose
of each drug (Table 2). For oxybutynin, 56.8% of
the claims were written by general practitioners
and 36.6% by urologists, compared to 40.5% by
general practitioners and 51.4% by urologists for
flavoxate (Table 2). When patients were catego-
rized into low (5 mg per day of oxybutynin or 200
mg per day of flavoxate), medium (7.5 mg per day
of oxybutynin and 400 mg per day of flavoxate)
or high (10 mg or 15 mg per day of oxybutynin
and 600 mg or 800 mg per day of flavoxate) treat-
ment groups, 59.1% of the flavoxate patients fell
into the last group, compared to 37.9% of the oxy-
butynin group (
 
P
 
 
 

 
 .001). In contrast, 44.8% of
the oxybutynin patients received a low daily dose
vs. only 15.5% for the flavoxate patients (
 
P
 
 
 

 
.001) (Table 2). The duration of claims was simi-
lar for both groups, and for the majority of pa-
tients (70% of the oxybutynin patients and 60%
of the flavoxate patients) claims were for 30 days
(data not shown).
To determine how many patients renewed their
first prescription, renewal rates for both groups
were determined over short and long time-frames
(based on the date of the index claim). Over the
short time period (1.5 times the period of the first
claim), renewal rates for oxybutynin were higher
than for flavoxate (Table 2), although the differ-
ence was not statistically significant. Nonetheless,
for the former group only 39.3% of the patients
renewed their first claim compared to 36.6% in
the flavoxate group. Over the 4-year period,
63.9% of the patients initially receiving oxybuty-
nin eventually filled another prescription, com-
pared to 55.5% of the flavoxate patients, a statis-
tically significant difference (
 
P
 
 
 

 
 .001).
The rate of switches from oxybutynin to fla-
voxate or flavoxate to oxybutynin was determined
either in patients with no previous prescription re-
newals and a switch to the other drug or in pa-
tients who switched to the other drug after any
number of renewals (Table 2). In both cases (Ta-
ble 2) fewer patients switched from oxybutynin to
flavoxate and the differences were statistically sig-
nificant (
 
P
 
 
 

 
 .001). There was more than a two-
fold difference in the switch rates between the two
drugs (Table 2), although the actual rates were rel-
atively low for both drugs. Even for patients ini-
tially receiving flavoxate the maximum switch rate
to oxybutynin was 5.9%. There was no additional
switching to other incontinence drugs since oxybu-
tynin and flavoxate are the only drugs listed in this
therapeutic category on the Québec formulary [18].
To estimate the factors affecting the overall
probability of a patient continuing on either oxy-
butynin or flavoxate, survival curves were plotted
for both drugs with survival time defined as the
number of days until cessation of the first treat-
 
Table 2
 
Prescription parameters and renewal and switch rates for urinary 
incontinence medication
 
% of patients
Variable
Oxybutynin 
(
 
n
 
 
 

 
 5718)
Flavoxate 
(
 
n
 
 
 

 
 972)
 
P
 
 value
Prescribing physician
General practitioner 56.8 (55.5, 58.1)* 40.5 (37.4, 43.6)
 

 
.001
Urologist 36.6 (35.4, 37.8) 51.4 (48.3, 54.5)
 

 
.001
Other 6.6 (6.0, 7.2) 8.1 (6.4, 9.8) .079
Drug dispensation (dose)
 
†
 
Low 44.8 15.5
 

 
.001
Med 17.3 25.4
 

 
.001
High 37.9 59.1
 

 
.001
Renewal rate
 
‡
 
Short time-frame
 
§
 
39.3 (38.0, 40.6) 36.6 (33.6, 39.6) .110
Long time-frame 63.9 (62.7, 65.1) 55.5 (52.4, 58.6)
 

 
.001
Switch rate
 
‡
 
No renewals
 
¶
 
1.3 (1.0, 1.6) 3.1 (2.0, 4.2)
 

 
.001
After renewals 2.2 (1.8, 2.6) 5.9 (4.4, 7.4)
 

 
.001
 
*Values in parentheses are the 95% confidence intervals.
 
†
 
Low (1 tablet per day); Medium (1.5 tablets per day for oxybutynin, 2 for flavoxate); High (2–3 tablets per day for
oxybutynin, 3–4 for flavoxate). Drugs were dispensed as 5 mg and 200 mg tablets for oxybutynin and flavoxate,
respectively.
 
‡
 
Rates are expressed as percentages, based on the number of patients renewing or switching claims with respect to
the total number of patients with a first claim for each drug.
 
§
 
Renewal in a short time-frame must take place within a maximum period of 1.5 times the duration of the previous
claim or seven days after termination of the previous claim.
 
¶
 
Switch rates, calculated over a short time-frame, are presented for patients with no renewals of the original claim
and for patients with any number of renewals before the switch.
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ment (Fig. 1). In all cases, the probabilities of sur-
vival were corrected for censoring (i.e., the end of
a data file in the database or the death of a pa-
tient). The survival curves showed that few pa-
tients maintained continuous treatment with ei-
ther incontinence drug for prolonged periods.
Three months after treatment commenced, ap-
proximately 78% of the oxybutynin and 83% of
the flavoxate patients had ceased treatment (Fig.
1). In addition, the probability of a patient with UI
taking oxybutynin for 6 months was only 11.4%,
compared to 5.7% for a patient prescribed flavox-
ate. A regression analysis of the combined survival
data for both drugs (Table 3), adjusted for the six
independent model variables, indicated that risk
ratios for all variables were close to 1.0. However,
patients receiving a high daily dose of either drug
had a 1.45 increased risk of early discontinuation,
compared to patients receiving a low daily quan-
tity, indicating that the higher the dose the more
likely the patient was to discontinue treatment.
Similarly, patients receiving flavoxate had an in-
creased risk of discontinuation (1.13-fold higher)
compared to those receiving oxybutynin (Table 3).
 
Discussion
 
In the present study, prescription renewal and
switch rates in an elderly population suffering
Figure 1 Survival curves for the number of days until cessation of the first treatment with oxybutynin () or flavoxate (). For
this analysis a patient was considered on treatment as long as prescriptions were renewed within a time period corresponding
to a maximum of 1.5 times the duration of the previous claim (for prescriptions of greater than 14 days duration) or seven days
after termination of the previous claim. The P value (0.001), determined by a log-rank test, indicated a significant difference
between the two curves.
Table 3 Regression analysis of survival data using Cox’s 
semiparametric model
 
Explanatory Variables* Risk ratio
 
P
 
 value
Daily quantity
 
†
 
Low Reference
Medium 1.13
(1.05, 1.21)
 
‡
 

 
 .001
High 1.45
(1.37, 1.53)
 

 
 .001
Physician
GP/others Reference
Urologist 0.99
(0.94, 1.05)
.766
Age
 

 
77.5 Reference
77.5–83.5 0.90
(0.85, 0.96)
 

 
 .001
 

 
83.5 0.86
(0.81, 0.92)
 

 
 .001
Sex
Women Reference
Men 1.01
(0.96, 1.06)
.786
Drug
Oxybutynin Reference
Flavoxate 1.13
(1.05, 1.22)
 

 
 .001
Chronic desease
score (CDS)
CDS 
 

 
 X Reference
CDS 
 

 
 X 
 

 
 1 0.95
(0.94, 0.96)
 

 
 .001
 
*Explanatory variables are those applying at the time of the first dispensation.
 
†
 
Low (1 tablet per day); medium (1.5 tablets per day for oxybutynin, 2 for fla-
voxate); high (2–3 tablets per day for oxybutynin, 3–4 for flavoxate). Drugs
were dispensed as 5 mg and 200 mg tablets for oxybutynin and flavoxate,
respectively.
 
‡
 
Values in parentheses are the 95% confidence intervals.
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from UI were used to assess oxybutynin and fla-
voxate use in an actual medical practice setting.
These data demonstrate that incontinence drugs
are poorly utilized by this patient population.
Only 39.3% of the oxybutynin and 36.6% of the
flavoxate patients even renewed their first drug
claim within a time-frame that would suggest at
least an initial desire to use the drugs in a continu-
ous manner. Even when the window for prescrip-
tion renewals was expanded to a 4-year period,
the data indicated that 36.1% of the oxybutynin
and 44.5% of the flavoxate patients never re-
newed their prescriptions following the first claim.
This high discontinuation rate in clinical practice
exceeds the high drop-out rate reported for pa-
tients in clinical trials taking anti-incontinence
drugs [12,14,16]. The drop-out rates in clinical
trials reflect the level of adverse events associated
with the use of anticholinergic drugs such as oxy-
butynin in incontinence therapies; in some studies
up to 25% of patients discontinued treatment ei-
ther as a result of these events or a general discon-
tent with the benefits [12,14,21].
Protocol-driven clinical trials may not accu-
rately reflect clinical practice since most trials only
examine drug use and outcomes for short periods
of time in a highly controlled environment. The
longer-term data described in the present study
suggest that discontinuation rates, as assessed by
the absence of drug renewals, may be much higher
than the rates determined from clinical trials. In
this analysis they were as high as 89% for oxy-
butynin and 94% for flavoxate, after only 6
months of therapy.
There are few published studies that have at-
tempted to assess how patients treat their inconti-
nence over the long term. In the United Kingdom,
Baigrie et al. [19], using patient prescription pat-
terns for oxybutynin (which in some cases covered
a period of five years), found that of 180 inconti-
nent patients, 57% derived a benefit from the
drug while 76% reported varying degrees of side-
effects. As a direct result of these side-effects, 23%
of the patients discontinued therapy, a figure con-
siderably lower than the apparent levels of discon-
tinuation reported in the present study. Over the
long-term, however, only 35 patients (19% of the
total) took the drug for more than 1 year and only
13 (7% of the total) of those took oxybutynin for
more than 3 years. This study therefore provides
further evidence that long-term adherence to oxy-
butynin for incontinent patients is poor. Baigrie et
al. [19] report that a number of patients initially
helped by oxybutynin subsequently abandoned
the drug because a clinical benefit was no longer
obtained. This may also be one reason why discon-
tinuation rates were so high in the present study.
However, comparisons of this nature are difficult
because of the complexity of incontinence and the
influence that a variety of factors, including patient
age and comorbidity [10,12], inaccurate diagnosis,
drug dose and additional nonpharmacological treat-
ments [13], might have on patient outcome.
There are several limitations to the present
study, relating to the information available from
the RAMQ database. Although the medical ser-
vices database component can be used to assess
general health status, it is limited by the fact that
doctors must enter a single patient diagnosis for
the claim to be processed. Thus, for individuals
over the age of 65 (who are more likely to have
multiple diseases than a younger population), the
single diagnosis recorded for each visit does not
provide a true picture of their overall medical con-
dition. In addition, neither the pharmaceutical nor
the medical database components contain records
on patient response to treatment or to changes in
treatment necessitated by clinical changes. Finally,
as with most retrospective drug claim databases,
records relate only to claims and any analysis of
the data assumes that patients actually consume
the dispensed drugs. Nevertheless, the RAMQ da-
tabase provides an excellent tool for the assess-
ment of drug exposure and previous studies have
shown that the database is accurate to within
3.1% for prescription claims [22].
The RAMQ database records do indicate that
oxybutynin is strongly favored by physicians over
flavoxate for the treatment of UI/detrusor instabil-
ity in Québec since the majority of the prescrip-
tions were for oxybutynin. This is not unexpected
since there is little evidence to suggest that flavox-
ate has any clinical impact on the treatment of de-
trusor instability. In a placebo-controlled cross-
over study, Chapple et al. [16] determined that
flavoxate, at a dose of 200 mg 3 times per day, of-
fered no clinical advantage to patients suffering
from detrusor instability. In the present study, pre-
scription renewal rates for patients receiving flavox-
ate were even lower than for those receiving oxybu-
tynin and survival analysis indicated that flavoxate
patients stopped their medication sooner.
In contrast, there is strong clinical evidence to
suggest that oxybutynin can be an efficacious
agent in the control of overactive bladder/detrusor
instability, although its use is associated with an
array of adverse events [12]. However, the present
study demonstrates that long-term patient compli-
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ance with oxybutynin therapy is also poor and only
marginally better than that of flavoxate [16,17].
Despite its limitations, the present study sug-
gests that in the population of elderly people de-
fined for the analysis, short-and long-term pharma-
cotherapy of UI with oxybutynin or flavoxate has
very limited success, presumably because of the ad-
verse events associated with their use and/or because
patients found treatment ineffective. Ineffective care
of this population means that substantial numbers
of incontinent patients live with their condition and
suffer the subsequent clinical, social, physical, and
psychological consequences [23]. In addition, un-
successful treatment may have substantial direct
medical cost consequences since incontinent pa-
tients have increased medical problems and a
greater risk of hospitalization and nursing home
admission [6]. The cost of UI consequences could
be reduced if incontinence symptoms were effec-
tively controlled. In addition, the poor compliance
with these drugs, particularly oxybutynin, suggest
that healthcare resources invested in drugs currently
available for the management of detrusor instability
do not provide adequate clinical returns.
 
This study was made possible by a grant from Pharmacia
& Upjohn. The paper was written with the collaboration
of John McCormick, PhD, Quintiles Canada, Inc.
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